Why an 18% Rally Still Leaves CoreWeave 66% Below Its Highs
As seen on the 24/7 Wall St. homepage on November 11, 2026.
AI Rally Sets Emerging Stocks Up for Best Streak Since September
- Bloomberg's Brody Ford: CoreWeave eased financing fears via customer prepayments and vendor financing, likely from Nvidia
- Even after the jump, CoreWeave remains down more than 66% from its highs
- Anthropic's IPO is already multiple times oversubscribed, with bankers weighing a $1.5 trillion valuation
- J&J backed psychedelic-inspired biotech Delics with a $100 million oversubscribed round
The relief rally in CoreWeave rests on creative funding: prepayments and vendor financing bought time, and the stock is still more than 66% below its highs. Anthropic's oversubscribed IPO book at a $1.5 trillion valuation is the next read on how much AI spending the market will underwrite.
Continue ReadingShow less
CoreWeave's raised annual revenue forecast drove shares up as much as 18%, its biggest single-session gain since August. Bloomberg's Brody Ford said the results eased analyst worries about the company's financing without fully removing them.
The company leaned on customer prepayments and vendor financing, likely from Nvidia, to shore up its balance sheet. That creative funding buys time while tying the company's footing to the goodwill of key partners and customers rather than conventional capital markets.
Even with the pop, CoreWeave remains more than 66% below its highs, so the market is still pricing in meaningful financing risk.
Sponsored
Anthropic's IPO book is already multiple times oversubscribed, and how that deal prices will test how much AI spending the broader market will underwrite.
Johnson and Johnson backed Delics, a psychedelic-inspired biotech, with an oversubscribed $100 million round. Deep-pocketed strategics are still hunting for high-conviction bets outside mainstream therapeutics.
